



## **Percutaneous thermal ablation of primary and secondary lung tumors: Comparison between microwave and radiofrequency ablation**

V. Aufranc, G. Farouil, M. Abdel-Rehim, P. Smadja, M. Tardieu, S. Aptel, A. Guibal

### **► To cite this version:**

V. Aufranc, G. Farouil, M. Abdel-Rehim, P. Smadja, M. Tardieu, et al.. Percutaneous thermal ablation of primary and secondary lung tumors: Comparison between microwave and radiofrequency ablation. *Diagnostic and Interventional Imaging*, 2019, 100, pp.781 - 791. <10.1016/j.diii.2019.07.008>. <hal-03489243>

**HAL Id: hal-03489243**

**<https://hal.science/hal-03489243v1>**

Submitted on 21 Jul 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC 4.0 - Attribution - Non-commercial use - International License

# **Percutaneous thermal ablation of primary and secondary lung tumors: comparison between microwave and radiofrequency ablation**

Short title:

## **MWA vs. RFA for lung tumors**

V. Aufranc<sup>1\*</sup>, G. Farouil<sup>2</sup>, M. Abdel-Rehim<sup>2</sup>, P. Smadja<sup>2</sup>, M. Tardieu<sup>2</sup>, S. Aptel<sup>2</sup>, A. Guibal<sup>2</sup>

<sup>1</sup> Department of Medical Imaging, CHU Montpellier-Lapeyronie, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier cedex 5, France

<sup>2</sup> Department of Medical Imaging, Hôpital Saint Jean, 66000 Perpignan, France

**Corresponding author:** Vincent Aufranc

Email: [vincent.aufranc@gmail.com](mailto:vincent.aufranc@gmail.com)

## Abstract

**PURPOSE.** The purpose of this study was to retrospectively compare microwave (MWA) and radiofrequency (RFA) ablation in the percutaneous treatment of primary and secondary lung tumors.

**MATERIAL AND METHODS.** A total of 115 patients with a total of 160 lung tumors (primary,  $n = 41$ ; secondary,  $n = 119$ ) were retrospectively included. There were 56 men and 59 women with a mean age of  $67.8 \pm 12.7$  (SD) years (range: 42-89 years) who underwent either MWA (61 patients; 79 tumors) or RFA (54 patients; 81 tumors). The primary study endpoints were local recurrence during follow-up and the incidence of complications during and following thermal ablation. The MWA and RFA groups were compared in terms of treatment efficacy and complication rates.

**RESULTS.** Demographics were similar in the two groups. Mean tumor diameter was smaller in RFA group ( $13.1 \pm 5.1$  [SD] mm; range: 4-27 mm) than in MWA group ( $17.1 \pm 8.3$  [SD] mm; range: 5-36 mm) ( $P < 0.001$ ). Ablation volumes at one month were  $24.1 \pm 21.7$  (SD)  $\text{cm}^3$  (range: 2-97.8  $\text{cm}^3$ ) in RFA group and  $30.2 \pm 35.9$  (SD)  $\text{cm}^3$  (range: 1.9-243.8  $\text{cm}^3$ ) in MWA group ( $P = 0.195$ ). During a mean overall follow-up duration of  $488 \pm 407$  (SD) days (range: 30-1508 days), 9/160 tumors (5.6%) developed local recurrence: six (6/79; 7.6%) in the RFA group and three (3/81; 3.7%) in the MWA group ( $P = 0.32$ ). Pneumothoraxes were more frequent in the RFA group (32/79; 40.5%) than in the MWA group (20/81; 24.7%) ( $P = 0.049$ ). The mean length of hospital stay was  $4.5 \pm 3.7$  (SD) days (range: 1-25 days) in the RFA group and  $4.7 \pm 4.6$  (SD) days (range: 2-25 days) in the MWA group ( $P = 0.76$ ).

**CONCLUSIONS.** MWA favorably compares with RFA and can be considered as an effective and safe thermal ablation technique for lung tumors, especially in situations where RFA has limited efficacy.

**Keywords:** Microwaves; Radiofrequency ablation (RFA); Thermal ablation techniques; Lung neoplasms; Percutaneous treatment.

## Abbreviations and acronyms

Non-small cell lung cancer: NSCLC

Radiofrequency ablation: RFA

Microwave ablation: MWA

## **Funding sources**

This research did not receive any specific grants from funding agencies in the public, commercial or not-for-profit sectors.

## **Introduction**

Lung cancer is the most common malignancy in the world [1]. It is also the leading cause of cancer-related mortality in both men and women: there are approximately 1.6 million deaths each year [1]. However, about 20% of patients with Stage I non-small cell lung cancer: (NSCLC) are not candidate to surgery due to comorbidities [2,3,4]. Moreover, the lungs are the second most frequent site for secondary extra-thoracic malignant tumors, often markers of poor prognosis [5]. Many studies have shown the potential efficacy of metastasectomy in selected patients [6,7,8].

Several studies have shown the benefits of less invasive techniques than surgery, such as stereotactic body radiation therapy [9] and percutaneous thermal ablation. Radiation therapy is an effective option for patients who are unable to tolerate lung surgery because of impaired cardiorespiratory function, but it has some limitations such as the occurrence of radiation pneumonitis [10-12].

Several studies have proven the efficacy of percutaneous thermal ablation as a second line of treatment for Stage I NSCLC and lung metastases [13,14]. Moreover, thermal ablation can be repeated during follow-up in the event of recurrence, which is less the case with surgery and stereotactic radiotherapy [15]. RFA is the oldest and most frequently used technique: it was first used for the treatment of pulmonary lesions since 2000 [16]. RFA consists in applying a sinusoidal current (420 to 500 kHz) to the tumor with straight or deployable electrodes, in order to obtain cell necrosis via temperatures above 70°C [17,18]. Since air has low electrical conductivity and high heat insulation, it induces the protection of the adjacent lung parenchyma but decreases the possibility of healthy resection margins [19,20]. Moreover, the proximity of > 3 mm vessels causes a sudden reduction in temperature, also known as the “heat sink effect” [21]. These two parameters lead to an increase in the theoretical risk of non-healthy margins [22,23].

On the opposite, MWA uses an ellipsoidal microwave field around the needle, between 915 and 2450 MHz [24,25]. The oscillation of the electromagnetic field causes a rapid flip movement of water molecules, causing the tissues to be warmed [24,25]. MWA is not subject

to low lung electrical conductivity, enabling larger ablation zones [19,26] Moreover, this technique is less affected by the heat sink effect as it coagulates the small surrounding vessels, which do not stop the heat conductivity of the tissue [19,25,26]. To our knowledge, only a few studies have compared the long-term efficacy of these two techniques [27–31].

The purpose of this study was to retrospectively compare MWA and RFA in the percutaneous treatment of primary and secondary lung tumors.

## **Materials and methods**

### *Population*

This retrospective study received institutional review board approval and informed consent was obtained from all patients. We analyzed the files of patients who underwent pulmonary thermal ablation in our institution between March 2013 and February 2018. The inclusion criteria were as follows: (i) Patients with primary or secondary lung tumor; (ii) Patients considered inoperable due to clinical, functional or biological data, with an estimated life expectancy greater than six months, for whom the decision of curative thermal ablation treatment was made in a multidisciplinary meeting. In the event of tumor recurrence, patients treated with RFA or MWA and meeting these criteria were also included. The exclusion criteria were as follows: (i) simultaneous extra-thoracic or thoracic lesions inaccessible with thermal ablation at the time of treatment; (ii) contraindication for general anesthesia; and (iii) severe coagulopathy or no stop of anti-platelet therapy prior to treatment.

We initially retrieved 152 patients who had a consultation for lung thermal ablation in our institution between March 2013 and February 2018. Among them, 37 were excluded: 21 had new extra-thoracic lesions on the chest CT scan performed before the consultation, 10 refused the treatment and 6 did not stop their anti-platelet therapy. Figure 1 shows the flow chart of patients who were considered for this study. Our study population included 115 patients. There were 56 men and 59 women with a mean age of  $67.8 \pm 12.7$  (standard deviation [SD]) years (range: 42-89 years).

### *Intervention and follow-up*

All patients had a consultation with a radiologist before treatment, to ensure the feasibility of thermal ablation and check for absence of any contraindications. They had an anesthetic consultation and had blood tests to check that there were no coagulation abnormalities.

The interventions were performed under general anesthesia, with the ongoing presence of an anesthesiologist during the procedure. For both RFA and MWA, the intervention was performed under CT fluoroscopy (BrightSpeed™, General Electric Healthcare) by one of three interventional radiologists with 7-, 10- and 15-years of experience in percutaneous thermal ablation. A biopsy was performed during treatment when the tumor histology was not known. A thermocouple was used to control the temperature if there was a risk of damaging a nearby organ.

To choose between the two techniques, we considered the following principles: RFA was favored since we had more experience with this technique. In the event of a tumor > 25 mm, or when the tumor was near a vessel greater than 3 mm in diameter, MWA was selected. MWA was preferred when there were multiple lesions to treat (at least two lesions in the same lung).

For RFA treatment, a generator (RF 3000™, Boston Scientific) and a 14 G needle electrode with a co-axial system (LeVein CoAccess™, Boston Scientific) were used (Fig. 2). If necessary, the RFA needle was repositioned to complete the ablation, depending on the volume of the target lesion. Dispersion electrodes were placed on the patients' thighs. The treatment wattage and duration used were based on the manufacturer's chart (range: 25 - 180 W). For MWA treatment a microwave generator and a 16-G probe (AMICA MWA System™; Hospital Service) were used (Fig. 3). From experience, we mainly treated with 40 W power (range: 20 - 80 W).

At the end of the thermal ablation therapy, a plain chest CT examination was performed to search for complications such as pneumothorax, intra-alveolar hemorrhage or bronchial fistulization (Fig. 4). In case of pneumothorax, we proceeded as follows: when the pneumothorax was minimal and well tolerated, the patient had no drain placement. In other situations, a drain (Skater™ 8F, Argon Medical) was positioned within the pneumothorax. To avoid another puncture site, whenever it was possible and safe, the drain was inserted via the electrode entry point, running to the apical and anterior section of the largest area of the pneumothorax. The patient was then hospitalized in our institution and underwent chest X-ray six hours later. The patient was discharged after good clinical tolerance was obtained and normalization of chest X-ray findings.

The patients underwent follow-up unenhanced CT examination one month after thermal ablation, then every three months for one year.

## *Data analysis*

We classified the patients into two groups: RFA and MWA. For each patient, a radiology resident noted the following variables: age, sex, primary or secondary origin, site of the primary tumor, location of the lung lesion, and treatment modality. Tumor size was measured in the three planes on chest CT performed before thermal ablation. The following parameters were studied on control CT after thermal ablation: occurrence of pneumothorax (drained or not), intra-alveolar hemorrhage or bronchial fistulization (cavitation). Using the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) classification [32], undrained pneumothorax and intra-alveolar hemorrhage were classified as Grade 1 complications. Drained pneumothorax and bronchopleural fistulas were classified as Grade 2 and Grade 3 complications, respectively. The radiology resident also recorded the length of the hospital stay and the duration of follow-up. The diameter of the ablation zone was measured within the three planes and then its volume was calculated (length x width x height x  $\pi/6$ ) on CT examination performed at one month, which closely matches with gross pathologic ablation size [33]. Any recurrence by contact with thermal ablation or at a distance was noted, and the duration of disease-free survival was calculated (*i. e.*, time between thermal ablation and the first CT examination that showed recurrence). Lastly, we created a point cloud representing ablation time in MWA at 40W and ablation small diameter one month after treatment, to estimate the appropriate MWA duration to obtain a complete and safe ablation.

The primary study endpoints were local recurrence during follow-up and the incidence of complications during and following thermal ablation.

## *Statistical analysis*

Statistical analysis was performed by using XLSTAT<sup>TM</sup> (Addinsoft) software. Quantitative variables were expressed as means, SD, and ranges. Qualitative variables were expressed as raw numbers, proportions, and percentages. Comparisons between the groups were performed using Student *t*-test for continuous variables and chi-square tests with Yates correction for categorical variables. Correlation between axial tumor short diameter at one month after treatment and MWA duration was searched using the Pearson correlation test. *P* values < 0.05 were considered indicative of statistical significance.

## Results

### *Baseline characteristics and follow-up*

Among the 115 patients, 61 (61/115; 53%) had RFA and 54 (54/115; 47%) had MWA. There were no significant differences between the two groups in terms of age and sex distribution (Table 1). A total of 160 tumors were treated, including 41 (41/160; 25.6%) primary lung tumors and 119 (119/160; 74.4%) lung metastases. Seventy-nine tumors (79/160; 49.4%) were treated by RFA and 81 (81/160; 50.6%) by MWA. Before treatment, the mean largest diameters of the tumors was  $13.1 \pm 5.1$  (SD) mm (range: 4-27mm) in the RFA group and  $17.1 \pm 8.3$  (SD) mm (range: 5-36 mm) in the MWA group ( $P < 0.001$ ). No differences in largest tumor diameters were found between the two groups. We performed several sessions with multiple ablations: 15 (15/79; 19%) for RFA and 17 (17/81; 21%) for MWA. The mean follow-up time in the study population was 488.4 days, with no significant differences between RFA group ( $505.8 \pm 308$  [SD] days; range: 30-1509 days) and MWA group ( $471 \pm 299$  [SD] days; range: 30-1379 days) ( $P = 0.67$ ).

### *Treatment efficacy*

Technical success was observed in all procedures (160/160; 100%), yielding a technical success rate of 100% (Table 2). The mean duration of thermal ablation was  $15.35 \pm 6.6$  (SD) min (range: 2-45 min) for RFA and  $7.51 \pm 4.5$  (SD) min (range: 1-20 min) for MWA ( $P < 0.001$ ). After treatment, the mean volume of the ablation zone was  $27.2 \text{ cm}^3$ . No differences in mean volume of ablation zone were found between MWA group ( $30.2 \pm 35.9$  [SD]  $\text{cm}^3$ ; range: 2 -  $97.8 \text{ cm}^3$ ) and RFA group ( $24.1 \pm 21.7$  [SD]  $\text{cm}^3$ ; range 1.9 -  $243.8 \text{ cm}^3$ ) ( $P = 0.195$ ) (Fig. 5). No differences in sphericity indexes were found between tumors in the MWA groups ( $0.60 \pm 0.13$  [SD]; range: 0.33-0.88) and those in the RFA group ( $0.64 \pm 0.15$  [SD]; range: 0.34-0.94) ( $P = 0.16$ ). Figure 6 shows the linear correlation between lesion long diameter and respectively RFA and MWA short and long diameters one month after thermal ablation.

Among the 160 tumors treated, we observed a total of nine local recurrences during the follow-up. No differences in local recurrence rates were observed between the RFA group (6/79; 7.6%) and the MWA group (3/81; 3.7%) ( $P = 0.32$ ). Of these local recurrences, five were treated with RFA, two with MWA and one with cryotherapy, with good local control.



The remaining recurrence presented as a diffuse disease, with no indication for local curative treatment.

In addition, patients treated with RFA had a total of 18 distant pulmonary or extra-pulmonary recurrences (18/79; 22.8%) while 24 patients treated with MWA had distant recurrence (24/81; 29.6%) ( $P = 0.42$ ). Among them, the time before recurrence was  $306.75 \pm 223$  (SD) days (range: 30-745 days) for RFA and  $297.40 \pm 259$  (SD) days (range: 37-1024 days) for MWA ( $P = 0.89$ ). No differences in disease-free survival were found between RFA group ( $424.8 \pm 371.5$  [SD] days; range: 30-1471 days) and MWA group ( $333.1 \pm 313.2$  [SD] days; range: 37-1227 days) ( $P = 0.16$ ).

A linear relationship was found between small-diameter ablation zone at one month after MWA and the duration of the procedure at 40 W ( $R^2 = 0.6157$ ) (Fig. 7).

### *Side effects and complications*

No deaths were attributed to thermal ablation. No deaths occurred during the 30 days following thermal ablation. The most common complication was pneumothorax (excluding voluntary pneumothorax, induced to protect high-risk organs). A total of 52 pneumothoraces (52/160; 32.5%) were observed. They were more frequent in the RFA group (32/79; 40.5%) than in the MWA group (20/81; 24.7%) ( $P = 0.049$ ). Of these, 29 required drainage: 20 required drainage in the RFA group (20/79; 25.3%) compared to 9 in the MWA group (9/81; 11.1%) ( $P = 0.03$ ). Six RFA (6/79; 7.6%) and two MWA (2/81; 2.5%) procedures were complicated by intra-alveolar hemorrhage ( $P = 0.16$ ). Four bronchopleural fistulas were observed; three in the MWA group (3/81; 3.7%) and one in the RFA group (1/79; 1.2%) ( $P = 0.32$ ) (Fig. 3). There were no differences between the two groups in terms of Grade 1 and Grade 3 complications. No Grade 4, 5 or 6 complications were observed. Overall, the mean length of hospital stay was 4.57 days, with no differences between RFA ( $4.46 \pm 3.7$  [SD] days; range: 1-25 days) and MWA group ( $4.68 \pm 4.6$  [SD] days; range: 2-25 days) ( $P = 0.76$ ).

## **Discussion**

Considering our results, MWA can be considered as an effective and safe ablation technique for the treatment of primary and secondary inoperable lung tumors, as the local control rate was not statistically different between MWA and RFA. This rate is consistent with those reported in the literature. Of the few studies comparing these two pulmonary ablation

techniques, none showed superiority of RFA over MWA [27–30,34]. Only Macchi et al. included 52 patients prospectively in the LUMIRA study [27]. There were no statistical differences in terms of efficacy or complications between RFA and MWA [27]. In another study, Shi et al. retrospectively compared 43 patients treated with RFA and 32 treated with MWA [28]. The overall response rates were 79% and 69% respectively and the complication rates were 49% for RFA and 50% for MWA, without any significant differences between these two techniques[28].

MWA has a number of potential advantages. First, it provides a higher coagulation necrosis volume compared to RFA [25]. Second, MWA yields shorter ablation time by comparison with RFA. This enabled us to treat up to five lung metastases in a single session, which could be of interest for frail patients under general anesthesia with iterative treatments. Finally, the absence of limitation by the heat sink effect is an advantage for MWA, especially for tumors adjacent to blood vessels, to decrease the risk of incomplete ablation [36].

Several studies have demonstrated that RFA is an effective curative technique. However, it has some limitations [23]. De Baere et al. showed that tumors larger than 2 cm were an independent risk factor for local recurrence [13]. In these situations, RFA overlapping technique leads to a larger number of passages through the pleura, theoretically increasing the risk of complications, post-procedural pain and the duration of the procedure. For these reasons, in our opinion, MWA remains a preferred indication in this frequent situation, provided that the parameters of the procedure are controlled. A thermocouple can also be used to control the ablation volume, in order to obtain a sufficient volume to ensure healthy resection margins without damaging lung tissue. The thermocouple is therefore placed one centimeter away from the lesion, either where there is the highest risk of non-healthy margins, or else in contact with a nearby structure to avoid damaging it.

As demonstrated by our results, MWA can achieve a much larger ablation zone. However, in our study, the mean ablation volumes were similar in the two groups. These data appear reassuring since they indicate that MWA can be well controlled by appropriate monitoring and by choosing the right ablation parameters. From experience, the majority of our thermal ablations were performed at a 40 W voltage and duration between two and 10 minutes, leading to a satisfactory compromise between ablation volume control, duration, efficacy and safety of thermal ablation. A linear correlation seems to be the most accurate way to predict ablation zone diameter depending on MWA duration. Studies with larger population could help create charts for MWA in lung parenchyma similar to that made for renal tumors [37].

Another interesting finding of our study is that pneumothorax is less frequent in patients treated using MWA than in those treated using RFA. The main hypothesis is that MWA yields larger, unrestricted ablation volumes, responsible for necrosis phenomena with retraction and pleural inflammation, potentially limiting the risk of pneumothorax. The larger size of the RFA needle (14-G) compared to the MWA probe (16-G) can also partially explain this result [38]. However, this result should be interpreted with caution because of potential selection bias due to the retrospective nature of our study. Indeed, RFA was preferred in patients with emphysema, which is a risk factor for pneumothorax.

Our study had several limitations. First, the retrospective nature and the selection criteria between RFA and MWA led to selection bias, since the patients were not randomized to receive one treatment or another. In addition, our study was monocentric and the radiologists practicing this procedure had several years of experience with pulmonary or extra-pulmonary MWA. We did not collect functional data before or after the procedure. Moreover, even though this did not affect our main endpoints, our survival data were biased by the absence of some parameters such as the differentiation between primary and secondary tumors and the concomitant use of other treatments. Lastly, MWA and RFA were not performed in combination with immunomodulation treatment, which seems to be a promising therapeutic strategy [39].

In conclusion, MWA favorably compares with RFA and can be considered as an effective and safe thermal ablation technique for the treatment of lung tumors. MWA can be applied to tumors for which RFA might be not effective because of a tumor greater than 25 mm, a tumor close to a vessel greater than 3 mm in diameter or because of multiple lesions. Our results suggest that MWA may broaden the indications of pulmonary thermal ablation.

## **Conflicts of interest**

The authors declare no conflict of interest.

## References

- 1 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136: E359-86.
- 2 Kaifi JT, Gusani NJ, Deshaies I, Kimchi ET, Reed MF, Mahraj RP et al. Indications and approach to surgical resection of lung metastases. *J Surg Oncol* 2010; 102: 187–95.
- 3 Matsuoka K, Ueda M, Miyamoto Y. Risk factor for respiratory death after lung cancer surgery in octogenarians. *Asian Cardiovasc Thorac Ann* 2015; 23: 1044–9.
- 4 Khullar OV, Liu Y, Gillespie T, Higgins KA, Ramalingam S, Lipscomb J et al. Survival after sublobar resection versus lobectomy for clinical stage IA lung cancer: an analysis from the National Cancer Data Base. *J Thorac Oncol* 2015; 10: 1625–33.
- 5 Mohammed T-LH, Chowdhry A, Reddy GP, Amorosa JK, Brown K, Dyer DS et al. ACR Appropriateness Criteria® screening for pulmonary metastases. *J Thorac Imaging* 2011; 26: W1-3.
- 6 Treasure T, Milošević M, Fiorentino F, Macbeth F. Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? *Thorax* 2014; 69: 946–9.
- 7 Cheung FPY, Alam NZ, Wright GM. The past, present and future of pulmonary metastasectomy: a review article. *Ann Thorac Cardiovasc Surg* 2019; doi:10.5761/atcs.ra.18-00229.
- 8 Kondo H, Okumura T, Ohde Y, Nakagawa K. Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomes. *Int J Clin Oncol* 2005;10: 81-5.
- 9 Prezzano KM, Ma SJ, Hermann GM, Rivers CI, Gomez-Suescun JA, Singh AK. Stereotactic body radiation therapy for non-small cell lung cancer: a review. *World J Clin Oncol* 2019; 10: 14–27.
- 10 Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GMM. Stereotactic body radiation therapy for non-small cell lung cancer tumors greater than 5 cm: safety and efficacy. *Int J Radiat Oncol Biol Phys* 2015; 92: 325–31.
- 11 Antoni D, Srour I, Mornex F. Lung cancer: stereotactic body radiation therapy and surgery. *Cancer Radiother J Soc Francaise Radiother Oncol* 2015; 19: 371–6.
- 12 Chen L, Zhao Y, Xu F. Radiation pneumonitis after stereotactic body radiation therapy for early stage non-small cell lung cancer. *Zhongguo Fei Ai Za Zhi Chin J Lung Cancer* 2014; 17: 351–356.
- 13 de Baère T, Aupérin A, Deschamps F, Chevallier P, Gaubert Y, Boige V et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. *Ann Oncol* 2015; 26: 987–91.

- 14 Petrella F, Spaggiari L. Comparison of pulmonary metastasectomy and stereotactic body radiation therapy for the treatment of lung metastases. *J Thorac Dis* 2019; 11: S280–2.
- 15 Milano MT, Mihai A, Kong FMS. Review of thoracic reirradiation with stereotactic body radiation therapy: a focus on toxicity risks. *Pract Radiat Oncol* 2018; 8: 251–65.
- 16 Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H. Percutaneous radiofrequency ablation of malignancies in the lung. *AJR Am J Roentgenol* 2000; 174: 57–9.
- 17 Liu B, Ye X, Fan W, Li X, Feng W, Lu Q et al. Expert consensus on image-guided radiofrequency ablation of pulmonary tumors: 2018 edition. *Thorac Cancer* 2018; 9: 1194–208.
- 18 de Baere T. Radiofrequency ablation of liver and lung tumors. *J Radiol* 2011; 92: 825–34.
- 19 Brace CL. Radiofrequency and microwave ablation of the liver, lung, kidney and bone: What are the differences. *Curr Probl Diagn Radiol* 2009; 38: 135–43.
- 20 Alexander ES, Dupuy DE. Lung cancer ablation: technologies and techniques. *Semin Interv Radiol* 2013; 30: 141–50.
- 21 Goldberg SN. Radiofrequency tumor ablation: principles and techniques. *Eur J Ultrasound* 2001; 13: 129–47.
- 22 Vroomen LGPH, Petre EN, Cornelis FH, Solomon SB, Srimathveeravalli G. Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: What are the differences? *Diagn Interv Imaging* 2017; 98: 609–17.
- 23 Gillams AR, Lees WR. Radiofrequency ablation of lung metastases: factors influencing success. *Eur Radiol* 2008; 18: 672–7.
- 24 Brace CL. Microwave ablation technology: what every use should know. *Curr Probl Diagn Radiol* 2009; 38: 61–7.
- 25 Brace CL. Microwave tissue ablation: biophysics, technology, and applications. *Crit Rev Biomed Eng* 2010; 38: 65–78.
- 26 Planché O, Teriitehau C, Boudabous S, Robinson JM, Rao P, Deschamps F et al. In vivo evaluation of lung microwave ablation in a porcine tumor mimic model. *Cardiovasc Intervent Radiol* 2013; 36: 221–8.
- 27 Macchi M, Belfiore MP, Floridi C, Serra N, Belfiore G, Carmignani L et al. Radiofrequency versus microwave ablation for treatment of the lung tumours: LUMIRA (lung microwave radiofrequency) randomized trial. *Med Oncol* 2017; 34: 96.
- 28 Shi F, Li G, Zhou Z, Xu R, Li W, Zhuang W et al. Microwave ablation versus radiofrequency ablation for the treatment of pulmonary tumors. *Oncotarget* 2017; 8: 109791–8.
- 29 Chi J, Ding M, Shi Y, Wang T, Cui D, Tang X et al. Comparison study of computed tomography-guided radiofrequency and microwave ablation for pulmonary tumors: a retrospective, case-controlled observational study. *Thorac Cancer* 2018; 9: 1241–8.

- 30 Vogl TJ, Eckert R, Naguib NNN, Beeres M, Gruber-Rouh T, Nour-Eldin NEA. Thermal ablation of colorectal lung metastases: retrospective comparison among Laser-induced thermotherapy, radiofrequency ablation, and microwave ablation. *AJR Am J Roentgenol* 2016; 207: 1340–9.
- 31 Yuan Z, Wang Y, Zhang J, Zheng J, Li W. A meta-analysis of clinical outcomes after radiofrequency ablation and microwave ablation for lung cancer and pulmonary metastases. *J Am Coll Radiol* 2019; 16: 302–14.
- 32 Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the Cirse Classification System. *Cardiovasc Intervent Radiol* 2017; 40: 1141–6.
- 33 Kodama H, Ueshima E, Howk K, Lee SW, Erinjeri JP, Solomon SB et al. Temporal evaluation of the microwave ablation zone and comparison of CT and gross sizes during the first month post-ablation in swine lung. *Diagn Interv Imaging* 2019; 100: 279–85.
- 34 Palussière J, Catena V, Buy X. Percutaneous thermal ablation of lung tumors - Radiofrequency, microwave and cryotherapy: where are we going? *Diagn Interv Imaging* 2017; 98: 619–625.
- 35 Lubner MG, Brace CL, Hinshaw JL, Lee FT. Microwave tumor ablation: mechanism of action, clinical results, and devices. *J Vasc Interv Radiol* 2010; 21: S192-203.
- 36 Wright AS, Sampson LA, Warner TF, Mahvi DM, Lee FT. Radiofrequency versus microwave ablation in a hepatic porcine model. *Radiology* 2005; 236: 132–9.
- 37 Novanta A, Herpe G, Vesselle G, Guibal A, Velasco S, Chan P, et al. Chart for renal tumor microwave ablation from human study. *Diagn Interv Imaging* 2018;99:609-14.
- 38 Carrafiello G, Mangini M, Fontana F, Di Massa A, Ierardi AM, Cotta E et al. Complications of microwave and radiofrequency lung ablation: personal experience and review of the literature. *Radiol Med* 2012; 117: 201–13.
- 39 Takaki H, Cornelis FH. Can the combination of ablation and immunomodulation become the breakthrough of cancer treatment? *Diagn Interv Imaging* 2018; 99: 121–2.

## Legends for figures

**Figure 1.** Study flowchart.

**Figure 2.** 77-year-old woman with single lung metastasis from colorectal carcinoma of the left lower lobe that was treated by radiofrequency ablation (RFA). A, CT image in the axial plane obtained during RFA shows a deployable electrode inserted into a subpleural lung metastasis with an axial diameter of 15 mm (arrow). B, CT image in the axial plane obtained one month after RFA shows a “target-like” appearance with ground-glass opacification induced by RFA (arrow). C, CT image in the axial plane obtained 12 months after RFA shows size reduction of the lesion with residual scarring (arrow).

**Figure 3.** 70-year-old man with single lung metastasis from colorectal carcinoma in the right lower lobe that was treated by microwave ablation (MWA). A, CT image in the axial plane obtained during MWA shows MWA needle inserted into a subpleural, 31-mm large, pulmonary metastasis in the right lower lobe (arrow). B, CT image in the axial plane obtained one month after MWA shows a “target-like” appearance with ground-glass opacification induced by MWA (arrow). C, CT image in the axial plane obtained 12 months after MWA shows residual scarring with an axial diameter of 38 mm (arrow).

**Figure 4.** 62-year-old man with a primary lung tumor in the right upper lobe who developed bronchopleural fistula after microwave ablation (MWA). A, CT image in the coronal plane obtained before MWA shows a subpleural primary lung cancer, with an axial diameter of 30 mm (arrow). B, CT image in the axial plane obtained during thermal ablation shows MWA needle placed into the tumor. A trans-osseous approach was chosen to be parallel to the long axis of the lesion (arrow). C, CT image in the axial plane obtained during MWA. A pneumothorax (arrow) was created to protect the right brachial plexus during MWA. D, CT image in the axial plane obtained one month after MWA shows cavitation (arrow) attributed to a bronchopleural fistula. E, CT image in the axial plane obtained six months after MWA shows complete regression of the bronchopleural fistula and residual scarring with an axial diameter of 38 mm (arrow).

**Figure 5.** Box plots show ablation volumes (A) and short tumor diameters (B) one month after radiofrequency ablation (in blue) and microwave ablation (in green). The bars in the box represent (from bottom to top) the first quartile, the median and the third quartile. The lower and upper outside bars represent the minimum and the maximum values respectively. (RFA: Radiofrequency ablation; MWA: Microwave ablation)

**Figure 6.** Graphs show comparison between lesion long diameter and RFA (A) or MWA (B) short and long diameters: short diameters one month after ablation were consistently larger than lesion long diameter, while controlling ablation volumes. Each bar refers to a single tumor. (RFA: Radiofrequency ablation; MWA: Microwave ablation).

**Figure 7.** Graph shows linear correlation between microwave ablation time and short diameter at 40 W. (MWA: Microwave ablation)

**Table 1.** Baseline characteristics of 115 patients with 160 lung tumors who underwent thermal ablation.

**Table 2.** Procedure parameters, recurrences and complications in 115 patients with 160 lung tumors who underwent thermal ablation.

Assessed for eligibility (n = 152 patients)

Excluded patients (n = 37)

21 patients with new extra-thoracic lesions

10 patients refused treatment

6 patients did not stop antiplatelet therapy

Ultimately included patients (n = 115)


61 patients treated with RFA

54 patients treated with MWA











































Short diameter in MWA at 40W / Ablation time





Variable	Radiofrequency ablation	Microwave ablation	<i>P</i>
No. of patients	61 (61/115; 53%)	54 (54/115; 47%)	
Sex			0.94
	<i>Male</i> 29 (29/61; 47%)	27 (27/54; 50%)	
	<i>Female</i> 32 (32/61; 53%)	27 (27/54; 50%)	
Age (y)	67.4 ±14 [42-89]	68.1 ±11.7 [45-83]	0.57
No. of tumors	79 (79/160; 49%)	81 (81/160; 51%)	
Tumor origin			0.5
Primary	18 (18/79; 23%)	23 (23/81; 28%)	
Secondary	61 (61/79; 77%)	58 (58/81; 72%)	
	<i>Colorectal</i> 43 (43/61; 70%)	32 (32/58; 55%)	
	<i>Head &amp; Neck</i> 7 (7/61; 11%)	9 (9/58; 15%)	
	<i>Bladder</i> 3 (3/61; 5%)	1 (1/58; 2%)	
	<i>Breast</i> 2 (2/61; 3%)	1 (1/58; 2%)	
	<i>Kidney</i> 2 (2/61; 3%)	5 (5/58; 9%)	
	<i>Pancreas</i> 2 (2/61; 3%)	2 (2/58; 3%)	
	<i>Uterus</i> 2 (2/61; 3%)	8 (8/58; 14%)	
Largest tumor diameter (mm)	13.1 ± 5.1 [4-27]	17.1 ± 8.3 [5-36]	< 0.001
No. of sessions with multiple ablations	15 (15/79; 19%)	17 (17/81; 21%)	0.91

Note. Quantitative variables are expressed a mean ± SD; numbers in brackets are ranges. Qualitative variables are expressed as raw numbers, proportions; numbers in parentheses are percentages.

	Radiofrequency ablation	Microwave ablation	<i>P</i>
Ablation datas			
<i>Ablation duration (min)</i>	15.4 ±6.6 [2-45]	7.5 ±4.5 [1-20]	< 0.001
<i>Ablation volume (cm<sup>3</sup>)</i>	24.1 ±21.7 [2-97.8]	30.2 ±35.9 [1.9-243.8]	0.20
<i>Ablation short diameter (cm)</i>	2.7 ±0.9 [1.3-4.6]	2.8 ±1.1 [1-7]	0.36
<i>Technical success</i>	79 (79/79; 100%)	81 (81/81; 100%)	1
Follow-up duration (days)	505.8 ±308 [30-1509]	471 ±299 [30-1379]	0.67
Recurrences	24 (24/79; 30%)	27 (27/81; 33%)	0.82
<i>Local recurrences</i>	6 (6/79; 7.6%)	3 (3/81; 3.7%)	0.32
<i>Distant recurrences</i>	18 (18/79; 22.8%)	24 (24/81; 29.6%)	0.42
<i>Time before recurrence (days)</i>	306.8 ±223 [30-745]	297.4 ±259 [37-1024]	0.89
Disease-free survival (days)	424.8 ±371.5 [30-1471]	333.1 ±313.2 [37-1227]	0.16
Total pneumothorax	32 (32/79; 40.5%)	20 (20/81; 24.7%)	0.049
<i>Low abundance pneumothorax</i>	10 (10/79; 12.7%)	7 (7/81; 8.6%)	0.57
<i>Exsufflated pneumothorax</i>	2 (2/79; 2.5%)	4 (4/81; 4.9%)	0.68
<i>Drained pneumothorax</i>	20 (20/79; 25.3%)	9 (9/81; 11.1%)	0.03
Intra-alveolar hemorrhage	6 (6/79; 7.6%)	2 (2/81; 2.5%)	0.16
Bronchopleural fistula	1 (1/79; 1.2%)	3 (3/81; 3.7%)	0.32
Grade 1 complications	18 (18/79; 22.7%)	13 (13/81; 16%)	0.28
Grade 2 complications	20 (20/79; 25.3%)	9 (9/81; 11.1%)	0.03
Grade 3 complications	1 (1/79; 1.2%)	3 (3/81; 3.7%)	0.32
Grade 4, 5 and 6 complications	0 (0/79; 0%)	0 (0/81; 0%)	>0.99
Length of hospital stay (days)	4.5 ±3.7 [1-25]	4.7 ±4.6 [2-25]	0.76

**Note.** Quantitative variables are expressed a mean ± SD; numbers in brackets are ranges. Qualitative variables are expressed as raw numbers, proportions; numbers in parentheses are percentages.